Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 18, 2015 titled "Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA". Cadila heads for pharma's top 5
Cadila Healthcare's stock gained 2.6% to hit a new high of Rs 454.40 on Friday, before closing at its highest till date of Rs 442.85 Cadila posts 41% jump in net profit to Rs 391 cr
Healthcare player, Zydus Cadila (Cadila Healthcare), on Thursday reported consolidated net profit of Rs 391 crore for the second quarter ended September 2015, up by 41 per cent from Rs 278 crore r... Announces Q2 results, Results Press Release & Limited Review Report for the Quarter ended September 30, 2015
Cadila Healthcare Ltd has announced the following results for the quarter ended September 30, 2015:The Unaudited Standalone results for the Quarter ended September 30, 2015The Company has posted a net profit of Rs. 6140.80 million for the quarter ended September 30, 2015 as compared to Rs. 3656.10 million for the quarter ended September 30, 2014. Total Income has increased from Rs. 13966.00 million for the quarter ended September... Updates on Result of Postal Ballot
Cadila Healthcare Ltd has submitted to BSE a copy of Minutes of announcement of result of Postal ballot / e-voting by the Company on September 22, 2015. Shareholding Pattern For September 30, 2015
Cadila Healthcare Ltd has informed BSE about the Shareholding Pattern as on September 30, 2015. Q2 results on Oct 22, 2015
Cadila Healthcare Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on October 22, 2015, inter alia, to consider & approve the unaudited financial results for the quarter and half year ended on September 30, 2015 (Q2).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window will remain closed... Cadila Healthcare turns ex-stock split
Thus far in 2015, the stock has outperformed the market by gaining 30% against 3% decline in the S&P BSE Sensex. Fixes Record Date for Sub-division / Stock Split
Cadila Healthcare Ltd has informed BSE that the Company has fixed October 07, 2015 as the Record Date for the purpose of Sub-division / Stock Split of 1 (One) Equity Share of Face Value of Rs. 5/- each into 5 (Five) Equity Shares of the face value of Re. 1/- (One) each. Disclosure of Voting results of Postal Ballot (Clause 35A)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Clause 35A.